Seizures at stroke onset: A case-control study

Seizure. 2023 Dec:113:28-33. doi: 10.1016/j.seizure.2023.10.013. Epub 2023 Oct 29.

Abstract

Purpose: Seizures occurring at the immediate onset of a stroke, abbreviated "seizures at onset" (SaO), pose a diagnostic and therapeutic challenge for physicians. In this study, we report on the current clinical practice in managing stroke patients with SaO from a large tertiary stroke center in Germany.

Methods: We selected all patients with SaO and acute ischemic or hemorrhagic stroke admitted to the Department of Neurology at the University Hospital of Cologne between 2019 and 01-01 and 2020-12-31. SaO patients were then compared to patients with acute ischemic or hemorrhagic stroke without SaO from the local stroke registry. Further, we compared SaO patients who received intravenous recombinant tissue-type plasminogen activator (rt-PA) and/or mechanical thrombectomy with matched controls.

Results: Overall, 54 out of 2312 stroke patients (2.3 %) in the examined period presented with SaO. The most prevalent SaO semiology was focal to bilateral tonic-clonic (42.6 %). SaO was associated with hemorrhagic strokes and higher in-hospital mortality in all stroke patients. The rate of acute stroke therapy was not influenced by the occurrence of SaO. In patients that received acute stroke therapy, patients with SaO had higher scores on the National Institutes of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS) at admission, and longer door-to-needle times for the administration of rt-PA, while none of the examined outcome parameters revealed a difference between patients with and without SaO after adjusting for potential confounders.

Conclusion: Data show that SaO is rare in stroke patients but associated with more extensive strokes.

Keywords: Acute symptomatic seizure; Ischemic stroke; Large vessel occlusion; SaO; Seizure at stroke onset; rt-PA.

MeSH terms

  • Brain Ischemia* / drug therapy
  • Brain Ischemia* / therapy
  • Case-Control Studies
  • Fibrinolytic Agents / therapeutic use
  • Hemorrhagic Stroke* / complications
  • Hemorrhagic Stroke* / drug therapy
  • Humans
  • Seizures / drug therapy
  • Stroke* / drug therapy
  • Stroke* / therapy
  • Treatment Outcome

Substances

  • Fibrinolytic Agents